Skip to main content
Premium Trial:

Request an Annual Quote

Miragen Acquires microRNA Target Rights from T2cure

Premium

Miragen Therapeutics said this week that it has acquired from German biopharmaceutical firm T2cure the exclusive rights to technology and intellectual property related to the in vivo use of microRNA-92 as a therapeutic target.

According to the company, miR-92 is "a key regulator of neo-angiogenesis as part of ischemic disease, which may be relevant to peripheral arterial disease and other cardiovascular disorders."

A particular member of the miRNA family, miR-92a, "serves as a valuable therapeutic target in the setting of ischemic disease," and potentially other vascular disorders such as atherosclerosis, Miragen added.

Specific terms of the agreement were not disclosed, although Miragen said that T2cure retains the right to use modulators of miR-92 for "ex vivo treatment of cellular therapeutics."

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.